Aptamers to Proteins

The Aptamer Handbook: Functional Oligonucleotides and Their Applications

Volumn , Issue , 2006, Pages 131-166

  Nimjee, Shahid M ^a   Rusconi, Christopher P ^b   Sullenger, Bruce A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Regado Biosciences Inc   (United States)

Author keywords

Antibodies immunoglobulins; Aptamer handbook; Aptamers as protein inhibitors; Aptamers to proteins; Cell surface receptor cell adhesion molecules; Cytokines growth factors; in vitro selection of target binding oligonucleotides; Lipoproteins; Nucleic acid binding proteins; Peptides; Prion proteins; Serine proteases

Indexed keywords

EID: 84879838042     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608192.ch6     Document Type: Chapter

References (148)

1. Adamis, A. P., J. W. Miller, et al. (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118, 445-450.
2. Aurup, H., D. M. Williams, et al. (1992). 2l-Fluoro-and 2l-amino-2l-deoxynucleoside 5l-triphosphates as substrates for T7 RNA polymerase. Biochemistry 31, 9636-9641.
3. Bahner, I., K. Kearns, et al. (1996). Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in longterm culture. J Virol 70, 4352-4360.
4. Beg, A. A. and D. Baltimore (1996). An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274, 782-784.
5. Beigelman, L., J. A. McSwiggen, et al. (1995). Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 270, 25702-25708.
6. Bevilacqua, M. P., R. M. Nelson (1993). Selectins. J Clin Invest 91, 379-387.
7. Biesecker, G., L. Dihel, et al. (1999). Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42, 219-230.
8. Blakeman, B. (1999). Management of heparininduced thrombocytopenia: a cardiovascular surgeon's perspective. Semin Hematol 36(Suppl 1), 37-41.
9. Bless, N. M., D. Smith, et al. (1997). Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury. Curr Biol 7, 877-880.
10. Bock, L. C., L. C. Griffin, et al. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355, 564-566.
11. Bohjanen, P. R., R. A. Colvin, et al. (1996). A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res 24, 3733-3738.
12. Bridonneau, P., Y. F. Chang, et al. (1998). High-affinity aptamers selectively inhibit human nonpancreatic secretory phospholipase A2 (hnps-PLA2). J Med Chem 41, 778-786.
13. Browning, C. M., L. Cagnon, et al. (1999). Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 Tat activation-response RNA decoy. J Virol 73, 5191-5195.
14. Burgert, H. G., Z. Ruzsics, et al. (2002). Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 269, 273-318.
15. Chambers, C. A., M. S. Kuhns, et al. (2001). CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19, 565-594.
16. Charlton, J., G. P. Kirschenheuter, et al. (1997). Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library. Biochemistry 36, 3018-3026.
17. Conn, P. M. and W. F. Crowley, Jr. (1994). Gonadotropin-releasing hormone and its analogs. Annu Rev Med 45, 391-405.
18. Coughlin, S. R. (2000). Thrombin signalling and protease-activated receptors. Nature 407, 258-264.
19. Cullen, B. R., W. C. Greene (1989). Regulatory pathways governing HIV-1 replication. Cell 58, 423-426.
20. DeAnda, A., Jr., S. E. Coutre, et al. (1994). Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann Thorac Surg 58, 344-350.
21. Doring, G. (1994). The role of neutrophil elastase in chronic inflammation. Am J Resp Crit Care Med 150(Pt 2), S114-S117.
22. Doudna, J. A., T. R. Cech, et al. (1995). Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci USA 92, 2355-2359.
23. Drachman, D. B. (1994). Myasthenia gravis. N Engl J Med 330, 1797-1810.
24. Drolet, D. W., R. D. Jenison, et al. (1999). A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX). Comb Chem High Throughput Screen 2, 271-278.
25. Ehsan, A., M. J. Mann, et al. (2001). Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121, 714-22.
26. Eikelboom, J. W., G. J. Hankey (2002). Low molecular weight heparins and heparinoids. Med J Aust 177, 379-383.
27. Ellington, A. D., J. W. Szostak (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822.
28. Erickson, H. P., M. A. Bourdon (1989). Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol 5, 71-92.
29. Eyetech Study, G. (2002). Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22, 143-152.
30. Eyetech Study, G. (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110, 979-986.
31. Faulhammer, D., B. Eschgfaller, et al. (2004). Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ. RNA 10, 516-527.
32. Floege, J., T. Ostendorf, et al. (1999). Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 154, 169-179.
33. Fukuda, K., D. Vishnuvardhan, et al. (2000). Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. Eur J Biochem 267, 3685-3694.
34. Ginsberg, J. A., M. A. Crowther, et al. (2001). Anticoagulation therapy. Hematology 339-357.
35. Gounni, A. S., B. Lamkhioued, et al. (1994). High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 367, 183-186.
36. Gragoudas, E. S., A. P. Adamis, et al. (2004). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351, 2805-2816.
37. Green, L., D. Jellinek, et al. (1995). Nucleaseresistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 2, 683-695.
38. Green, L. S., D. Jellinek, et al. (1996). Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35, 14413-14424.
39. Griffin, L. C., G. F. Tidmarsh, et al. (1993). In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81, 3271-3276.
40. Heldin, C. H. (1992). Structural and functional studies on platelet-derived growth factor. EMBO J 11, 4251-4259.
41. Helmling, S., C. Maasch, et al. (2004). Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci USA 101, 13174-13179.
42. Henn, V., J. R. Slupsky, et al. (1998). CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591-594.
43. Hicke, B. J., A. W. Stephens (2000). Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest 106, 923-928.
44. Hicke, B. J., S. R. Watson, et al. (1996). DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. J Clin Invest 98, 2688-2692.
45. Hicke, B. J., C. Marion, et al. (2001). Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 276, 48644-48654.
46. Hiebert, S. W., M. Lipp, et al. (1989). E1A-dependent trans-activation of the human MYC promoter is mediated by the E2F factor. Proc Natl Acad Sci USA 86, 3594-3598.
47. Holash, J., P. C. Maisonpierre, et al. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998.
48. Huang, J., J. Moore, et al. (2001). Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg 36, 357-361.
49. Hunter, T. (1993). Braking the cycle. Cell 75, 839-841.
50. Hwang, B.. S. W. Lee. (2002). Improvement of RNA aptamer activity against myasthenic autoantibodies by extended sequence selection. Biochem Biophys Res Commun 290, 656-662.
51. Hwang, J., H. Fauzi, et al. (2000). The RNA aptamer-binding site of hepatitis C virus NS3 protease. Biochem Biophys Res Commun 279, 557-562.
52. Iida, H., R. Seifert, et al. (1991). Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci USA 88, 6560-6564.
53. Ishizaki, J., J. R. Nevins, et al. (1996). Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nature Med 2, 1386-1389.
54. Jaeger, J., T. Restle, et al. (1998). The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. EMBO J 17, 4535-4542.
55. Jahkola, T., T. Toivonen, et al. (1998). Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur J Cancer 34, 1687-1692.
56. Jain, R. K. (1987). Transport of molecules in the tumor interstitium: a review. Cancer Res 47, 3039-3051.
57. Jain, R. K. (1996). Delivery of molecular medicine to solid tumors. Science 271, 1079-1080.
58. Jellinek, D., L. S. Green, et al. (1994). Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 33, 10450-10456.
59. Jellinek, D., L. S. Green, et al. (1995). Potent 2l-amino-2l-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34, 11363-11372.
60. Jenison, R. D., S. D. Jennings, et al. (1998). Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev 8, 265-279.
61. Jochum, M., W. Machleidt, et al. (1993). Proteolysis-induced pathomechanisms in acute inflammation and related therapeutic approaches. Agents & Actions Suppl 42, 51-69.
62. Joshi, P., V. R. Prasad. (2002). Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol 76, 6545-6557.
63. Kettel, L. M., W. P. Hummel. (1997). Modern medical management of endometriosis. Obstet Gynecol Clin N Am 24, 361-373.
64. Kim, E. S., A. Serur, et al. (2002). Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99, 11399-11404.
65. Kohn, D. B., G. Bauer, et al. (1999). A clinical trial of retroviral-mediated transfer of a revresponsive element decoy gene into CD34+ cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94, 368-371.
66. Kojima, M., H. Hosoda, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762); 656-660.
67. Kramer, R. M., C. Hession, et al. (1989). Structure and properties of a human nonpancreatic phospholipase A2. J Biol Chem 264, 5768-5775.
68. Kubik, M., C. Bell, et al. (1997). Isolation and characterization of 2l-fluoro-, 2l-amino-, and 2l-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding. J Immunol 159, 259-267.
69. Kubik, M. F., A. W. Stephens, et al. (1994). High-affinity RNA ligands to human alphathrombin. Nucleic Acids Res 22, 2619-2626.
70. Kumar, P. K., K. Machida, et al. (1997). Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 237, 270-282.
71. Kvanta, A., P. V. Algvere, et al. (1996). Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Visual Sci 37, 1929-1934.
72. Lebruska, L. L., I. L. James Maher. (1999). Selection and characterization of an RNA decoy for transcription factor NF-B. Biochemistry 38, 3168-3174.
73. Lee, S. W., B. A. Sullenger. (1996). Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J Exp Med 184, 315-324.
74. Lee, S. W., B. A. Sullenger. (1997). Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nature Biotechnol 15, 41-45.
75. Lee, T. C., B. A. Sullenger, et al. (1992). Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 4, 66-74.
76. Lindner, V., M. A. Reidy. (1995). Platelet-derived growth factor ligand and receptor expression by large vessel endothelium in vivo. Am J Pathol 146, 1488-1497.
77. Lindner, V., C. M. Giachelli, et al. (1995). A subpopulation of smooth muscle cells in injured rat arteries expresses platelet-derived growth factor-B chain mRNA. Circ Res 76, 951-957.
78. Lisziewicz, J., D. Sun, et al. (1993). Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 90, 8000-8004.
79. Lupold, S. E., B. J. Hicke, et al. (2002). Identification and characterization of nucleasestabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62, 4029-4033.
80. Macaya, R., P. Schultze, et al. (1993). Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci USA 90, 3745-3749.
81. Mann, M. J., G. H. Gibbons, et al. (1999a). Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci USA 96, 6411-6416.
82. Mann, M. J., A. D. Whittemore, et al. (1999b). Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354, 1493-1498.
83. Marciniak, R. A., M. A. Garcia-Blanco, et al. (1990). Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus. Proc Natl Acad Sci USA 87, 3624-3628.
84. Meunier, J. C. (1997). Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur J Pharmacol 340, 1-15.
85. Molica, S., G. Vitelli, et al. (2002). Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer 86, 31-35.
86. Moll, S., H. R. Roberts. (2002). Overview of anticoagulant drugs for the future. Semin Hematol 39, 145-157.
87. Morgan, B. (1995). Physiology and pathophysiology of complement: progress and trends. Crit Rev Clin Lab Sci 32, 165-198.
88. Morishita, R., G. H. Gibbons, et al. (1995). A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 92, 5855-5859.
89. Morishita, R., T. Sugimoto, et al. (1997). In vivo transfection of cis element decoy against nuclear factor-kappaB binding site prevents myocardial infarction. Nature Med 3, 894-899.
90. Mulligan, M., E. Schmid, et al. (1997). C5adependent up-regulation in vivo of lung vascular P-selectin. J Immunol 158, 1857-1861.
91. Nair, S. K., A. Heiser, et al. (2000). Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.[see comment]. Nature Med 6, 1011-1017.
92. Nevins, J. R. (1992). E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258, 424-429.
93. O'Connell, D., A. Koenig, et al. (1996). Calcium-dependent oligonucleotide antagonists specific for L-selectin. Proc Natl Acad Sci USA 93, 5883-5887.
94. O'Malley, R. P., T. M. Mariano, et al. (1986). A mechanism for the control of protein synthesis by adenovirus VA RNAI. Cell 44, 391-400.
95. Oleksyszyn, J., J. C. Powers. (1989). Irreversible inhibition of serine proteases by peptidyl derivatives of alpha-aminoalkylphosphonate diphenyl esters. Biochem Biophys Res Commun 161, 143-149.
96. Oleksyszyn, J., J. C. Powers. (1991). Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. Biochemistry 30, 485-493.
97. Ostendorf, T., U. Kunter, et al. (2001). Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 12, 909-918.
98. Ostendorf, T., U. Kunter, et al. (2002). The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol 13, 658-667.
99. Paborsky, L., S. McCurdy, et al. (1993). The single-stranded DNA aptamer-binding site of human thrombin. J Biol Chem 268, 20808-20811.
100. Pierce, E. A., R. L. Avery, et al. (1995). Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92, 905-909.
101. Pietras, K., A. Ostman, et al. (2001). Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61, 2929-2934.
102. Proske, D., S. Gilch, et al. (2002). Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 3, 717-725.
103. Renfrey, S., C. Downton, et al. (2003). The painful reality. Nature Rev Drug Discov 2, 175-176.
104. Rimsza, L., K. Pastos, et al. (2003). Endothelial stimulation by small lymphocytic lymphoma correlates with secreted levels of basic fibroblastic growth factor. Br J Haematol 120, 753-758.
105. Rintala, E. M., T. J. Nevalainen. (1993). Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections. Clin Infect Dis 17, 864-870.
106. Rosen, L. S. (2001). Angiogenesis inhibition in solid tumors. Cancer J 7 (Suppl 3), S120-S128.
107. Rosen, L. S. (2002). Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9(2 Suppl), 36-44.
108. Rosen, S. D., C. R. Bertozzi. (1994). The selectins and their ligands. Curr Opin Cell Biol 6, 663-673.
109. Ruckman, J., L. S. Green, et al. (1998). 2l-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273, 20556-20567.
110. Rusconi, C. P., A. Yeh, et al. (2000). Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost 84, 841-848.
111. Rusconi, C. P., E. Scardino, et al. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90-94.
112. Rusconi, C. P., J. D. Roberts, et al. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22, 1423-1428.
113. Saedi, M. S., R. Anand, et al. (1990). Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis. FEBS Lett 267, 55-59.
114. Santulli-Marotto, S., S. K. Nair, et al. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res 63, 7483-7489.
115. Sawa, Y., R. Morishita, et al. (1997). A novel strategy for myocardial protection using in vivo transfection of cis element "decoy" against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury. Circulation 96(9 Suppl), II-280-284.
116. Schally, A. V. (1999). Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20, 1247-1262.
117. Schmidt, A. E., S. P. Bajaj. (2003). Structurefunction relationships in factor IX and factor IXa. Trends Cardiovasc Med 13, 39-45.
118. Seo, H.-S. and S.-W. Lee. (2000). In vitro selection of the 2l-fluoro-2l-deoxyribonucleotide decoy RNA inhibitor of myasthenia autoantibodies. J Microbiol Biotechnol 10, 7070-7013.
119. Smith, D., G. P. Kirschenheuter, et al. (1995). In vitro selection of RNA-based irreversible inhibitors of human neutrophil elastase. Chem Biol 2, 741-750.
120. Sullenger, B. A., H. F. Gallardo, et al. (1990). Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63, 601-608.
121. Sullenger, B. A., H. F. Gallardo, et al. (1991). Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 65, 6811-6816.
122. Sutton, B. J. and H. J. Gould. (1993). The human IgE network. Nature 366, 421-428.
123. Tasch, J., M. Gong, et al. (2001). A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy. Crit Rev Immunol 21, 249-261.
124. Tian, J. H., J. S. Han. (2000). Functional studies using antibodies against orphanin FQ/nociceptin. Peptides 21, 1047-1050.
125. Tomita, N., R. Morishita, et al. (2000). Transcription factor decoy for NFkappaB inhibits TNF-alpha-induced cytokine and adhesion molecule expression in vivo. Gene Ther 7, 1326-1332.
126. Tschop, M., D. L. Smiley, et al. (2000). Ghrelin induces adiposity in rodents. Nature 407, 908-913.
127. Tucker, C. E., L. S. Chen, et al. (1999). Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B, Biomed Sci Appl 732, 203-212.
128. Tuerk, C., L. Gold. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510.
129. Tuerk, C., S. MacDougal, et al. (1992). RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci USA 89, 6988-6992.
130. Ueno, T., Y. Sawa, et al. (2001). Nuclear factorkB decoy attenuates neuronal damage after global brain ischemia: A future strategy for brain protection during circulatory arrest. J Thorac Cardiovasc Surg 122, 720-727.
131. Ulrich, H., M. H. Magdesian, et al. (2002). In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J Biol Chem 277, 20756-20762.
132. Van Seventer, G. A., Y. Shimizu, et al. (1990). The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 144, 4579-4586.
133. Vater, A., F. Jarosch, et al. (2003). Short bioactive spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res 31, e130.
134. Verma, I. M., J. K. Stevenson, et al. (1995). Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 9, 2723-2735.
135. Wang, K., S. McCurdy, et al. (1993). A DNA aptamer which binds ro and inhibits thrombin exhibits a new structural motif for DNA. Biochemistry 32, 1899-1904.
136. Watson, S. R., Y. F. Chang, et al. (2000). Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev 10, 63-75.
137. White, R. R., B. A. Sullenger, et al. (2000). Developing aptamers into therapeutics. J Clin Invest 106, 929-934.
138. White, R., C. Rusconi, et al. (2001). Generation of species cross-reactive aptamers using toggle SELEX. Mol Ther J Am Soc Gene Ther 4, 567-573.
139. White, R. R., S. Shan, et al. (2003). Inhibition of rat corneal angiogenesis by a nucleaseresistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 100, 5028-5033.
140. Wiegand, T., P. Williams, et al. (1996). Highaffinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J Immunol 157, 221-230.
141. Willcox, N. (1993). Myasthenia gravis. Curr Opin Immunol 5, 910-917.
142. Willis, M. C., B. D. Collins, et al. (1998). Liposome-anchored vascular endothelial growth factor aptamers. [Erratum appears in Bioconjug Chem 1998 Sep-Oct;9(5):633.] Bioconjug Chem 9, 573-582.
143. Wlotzka, B., S. Leva, et al. (2002). In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci USA 99, 8898-8902.
144. Wren, A. M., L. J. Seal, et al. (2001a). Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86, 5992.
145. Wren, A. M., C. J. Small, et al. (2001b). Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 2540-2547.
146. Wu, Q., M. Tsiang, et al. (1992). Localization of the single-stranded DNA binding site in the thrombin anion-binding exosite. J Biol Chem 267, 24408-24412.
147. Yamamoto, R., M. Katahira, et al. (2000). A novel RNA motif that binds efficiently and specifically to the Tat protein of HIV and inhibits the trans-activation by Tat of transcription in vitro and in vivo. Genes Cells 5, 371-388.
148. Zhang, B., R. Roth. (1991). A region of the insulin receptor important for ligand binding (residues 450-601) is recognized by patients' autoimmune antibodies and inhibitory monoclonal antibodies. Proc Natl Acad Sci USA 88, 9858-9862.